This Article Full Text Full Text (PDF) All Versions of this Article: 91/8/2892    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Durante, C. Articles by Schlumberger, M. Search for Related Content PubMed PubMed Citation Articles by Durante, C. Articles by Schlumberger, M. Related Collections Thyroid Endocrine Oncology

Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy

Institut Gustave Roussy and University Paris Sud (C.D., E.B., S.L., D.H., J.P.T., B.C., M.R., J.D.L., M.S.), 94805 Villejuif, France; and Institut National de la Santé et de la Recherche Médicale Unité 605 (N.H., F.D.V.), Institut Gustave Roussy, 94805 Villejuif, France

Address all correspondence and requests for reprints to: Martin Schlumberger, M.D., Institut Gustave Roussy, 94805 Villejuif Cédex, France. E-mail: schlumbg{at}igr.fr.

Aim: The goal of this study was to estimate the cumulative activity of ¹³¹I to be administered to patients with distant metastases from thyroid carcinoma.

Methods: A total of 444 patients were treated from 1953–1994 for distant metastases from papillary and follicular thyroid carcinoma: 223 had lung metastases only, 115 had bone metastases only, 82 had both lung and bone metastases, and 24 had metastases at other sites. Treatment consisted of the administration of 3.7 GBq (100 mCi) ¹³¹I after withdrawal of thyroid hormone treatment, every 3–9 months during the first 2 yr and then once a year until the disappearance of any metastatic uptake. Thyroxine treatment was given at suppressive doses between ¹³¹I treatment courses.

Results: Negative imaging studies (negative total body ¹³¹I scans and conventional radiographs) were attained in 43% of the 295 patients with ¹³¹I uptake; more frequently in those who were younger, had well-differentiated tumors, and had a limited extent of disease. Most negative studies (96%) were obtained after the administration of 3.7–22 GBq (100–600 mCi). Almost half of negative studies were obtained more than 5 yr after the initiation of the treatment of metastases. Among patients who achieved a negative study, only 7% experienced a subsequent tumor recurrence. Overall survival at 10 yr after initiation of ¹³¹I treatment was 92% in patients who achieved a negative study and 19% in those who did not.

Conclusion: ¹³¹I treatment is highly effective in younger patients with ¹³¹I uptake and with small metastases. They should be treated until the disappearance of any uptake or until a cumulative activity of 22 GBq has been administered. In the other patients, other treatment modalities should be used when tumor progression has been documented.

This article has been cited by other articles:

				N. A. Johnson and M. E. Tublin Postoperative Surveillance of Differentiated Thyroid Carcinoma: Rationale, Techniques, and Controversies Radiology, November 1, 2008; 249(2): 429 - 444. [Abstract] [Full Text] [PDF]

				P. Zanotti-Fregonara, D. Rubello, and E. Hindie Bone Metastases of Differentiated Thyroid Cancer: The Importance of Early Diagnosis and 131I Therapy on Prognosis J. Nucl. Med., November 1, 2008; 49(11): 1902 - 1903. [Full Text] [PDF]

				M. Eszlinger, K. Krohn, S. Hauptmann, H. Dralle, T. J. Giordano, and R. Paschke Perspectives for Improved and More Accurate Classification of Thyroid Epithelial Tumors J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3286 - 3294. [Abstract] [Full Text] [PDF]

				S. I. Sherman, L. J. Wirth, J.-P. Droz, M. Hofmann, L. Bastholt, R. G. Martins, L. Licitra, M. J. Eschenberg, Y.-N. Sun, T. Juan, et al. Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer N. Engl. J. Med., July 3, 2008; 359(1): 31 - 42. [Abstract] [Full Text] [PDF]

				M M Muresan, P Olivier, J Leclere, F Sirveaux, L Brunaud, M Klein, R Zarnegar, and G Weryha Bone metastases from differentiated thyroid carcinoma Endocr. Relat. Cancer, March 1, 2008; 15(1): 37 - 49. [Abstract] [Full Text] [PDF]

				C. Lupi, R. Giannini, C. Ugolini, A. Proietti, P. Berti, M. Minuto, G. Materazzi, R. Elisei, M. Santoro, P. Miccoli, et al. Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4085 - 4090. [Abstract] [Full Text] [PDF]

				E. Hindie, P. Zanotti-Fregonara, I. Keller, F. Duron, J.-Y. Devaux, M. Calzada-Nocaudie, E. Sarfati, J.-L. Moretti, P. Bouchard, and M.-E. Toubert Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcome Endocr. Relat. Cancer, September 1, 2007; 14(3): 799 - 807. [Abstract] [Full Text] [PDF]

				M. Schlumberger, A. Hitzel, M. E. Toubert, C. Corone, F. Troalen, M. H. Schlageter, F. Claustrat, S. Koscielny, D. Taieb, M. Toubeau, et al. Comparison of Seven Serum Thyroglobulin Assays in the Follow-Up of Papillary and Follicular Thyroid Cancer Patients J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2487 - 2495. [Abstract] [Full Text] [PDF]

				C. Durante, E. Puxeddu, E. Ferretti, R. Morisi, S. Moretti, R. Bruno, F. Barbi, N. Avenia, A. Scipioni, A. Verrienti, et al. BRAF Mutations in Papillary Thyroid Carcinomas Inhibit Genes Involved in Iodine Metabolism J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2840 - 2843. [Abstract] [Full Text] [PDF]